Your email has been successfully added to our mailing list.

×
0.00152699182610261 0.0105092966855295 -0.00745531303332433 0.00152699182610261 0.0240725770232643 -0.0164376178927513 -0.0209736818467619 -0.016078325698374
Stock impact report

Akari up 28% premarket on advancement of nomacopan [Seeking Alpha]

Akari Therapeutics Plc ADS (AKTX)  More Company Research Source: Seeking Alpha
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
PDF Akari up 28% premarket on advancement of nomacopan Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX 28% Part A will confirm the dosing scheme while Part B will assess the efficacy of the confirmed dosing regimen. The trial should commence this month. Concurrently, the company announced [Read more]
Impact snapshot Event time: AKTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
AKTX alerts
from News Quantified
Opt-in for
AKTX alerts

from News Quantified
Opt-in for
AKTX alerts

from News Quantified